company background image
TOVX

Theriva Biologics NYSEAM:TOVX Stock Report

Last Price

US$1.07

Market Cap

US$16.2m

7D

18.2%

1Y

-54.9%

Updated

05 Feb, 2023

Data

Company Financials +

TOVX Stock Overview

Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need.

TOVX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

New

Notes are coming soon

Theriva Biologics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Theriva Biologics
Historical stock prices
Current Share PriceUS$1.07
52 Week HighUS$4.39
52 Week LowUS$0.39
Beta1.37
1 Month Change84.48%
3 Month Change46.46%
1 Year Change-54.87%
3 Year Change-81.31%
5 Year Change-99.27%
Change since IPO-99.82%

Recent News & Updates

Recent updates

David Lazar Just Bought 13% More Shares In Synthetic Biologics, Inc. (NYSEMKT:SYN)

Mar 07
David Lazar Just Bought 13% More Shares In Synthetic Biologics, Inc. (NYSEMKT:SYN)

Who Has Been Buying Synthetic Biologics, Inc. (NYSEMKT:SYN) Shares?

Feb 04
Who Has Been Buying Synthetic Biologics, Inc. (NYSEMKT:SYN) Shares?

Shareholder Returns

TOVXUS BiotechsUS Market
7D18.2%-0.8%1.7%
1Y-54.9%4.4%-9.6%

Return vs Industry: TOVX underperformed the US Biotechs industry which returned 4.4% over the past year.

Return vs Market: TOVX underperformed the US Market which returned -9.6% over the past year.

Price Volatility

Is TOVX's price volatile compared to industry and market?
TOVX volatility
TOVX Average Weekly Movement15.3%
Biotechs Industry Average Movement12.1%
Market Average Movement6.7%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: TOVX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: TOVX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a16Steve Shallcrosshttps://therivabio.com

Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company’s lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma.

Theriva Biologics, Inc. Fundamentals Summary

How do Theriva Biologics's earnings and revenue compare to its market cap?
TOVX fundamental statistics
Market CapUS$16.18m
Earnings (TTM)-US$19.70m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TOVX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$19.70m
Earnings-US$19.70m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.30
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.4%

How did TOVX perform over the long term?

See historical performance and comparison